Michael Friedländer
Impact in
- Reproductive Medicine top 0.01%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.02%
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
Papers in
- Oncology 222
- PARP inhibition in cancer therapy 105
- Cancer Treatment and Pharmacology 44
- Cancer survivorship and care 30
- Cancer Immunotherapy and Biomarkers 15
-
- Ovarian cancer diagnosis and treatment 159
- Co-authors
- David W. Hedley (9 shared papers)Ian W. Taylor (7 shared papers)Elizabeth A. Musgrove (3 shared papers)Catherine A. Rugg (1 shared paper)M. William Audeh (12 shared papers)Ursula A. Matulonis (24 shared papers)James Carmichael (4 shared papers)Clare L. Scott (25 shared papers)
- Journals
- Journal of Clinical Oncology (106 papers)Gynecologic Oncology (54 papers)International Journal of Gynecological Cancer (38 papers)Annals of Oncology (32 papers)European Journal of Cancer (15 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Michael Friedländer
478 papers receiving 27.1k citations
Michael Friedländer's Hit Papers
Peers
Comparison fields: 5 of 162
- Reproductive Medicine 7.0k
- Oncology 13.3k
- Obstetrics and Gynecology 1.9k
- Cancer Research 3.6k
- Genetics 4.1k
Countries citing papers authored by Michael Friedländer
This map shows the geographic impact of Michael Friedländer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Friedländer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Friedländer more than expected).
Fields of papers citing papers by Michael Friedländer
This network shows the impact of papers produced by Michael Friedländer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Friedländer. The network helps show where Michael Friedländer may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Friedländer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 493 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. Hit paper breakdown → | 1983 | 1806 |
| 2 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1748 |
| 3 | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Hit paper breakdown → | 2012 | 1363 |
| 4 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1296 |
| 5 | Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation Hit paper breakdown → | 2014 | 1248 |
| 6 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Hit paper breakdown → | 2014 | 1066 |
| 7 | BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group Hit paper breakdown → | 2012 | 868 |
| 8 | Chemotherapy‐induced peripheral neurotoxicity: A critical analysis Hit paper breakdown → | 2013 | 566 |
| 9 | Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup Hit paper breakdown → | 2009 | 502 |
| 10 | Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Hit paper breakdown → | 2011 | 459 |
| 11 | Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Hit paper breakdown → | 2014 | 433 |
| 12 | The importance of patient-reported outcomes in clinical trials and strategies for future optimization Hit paper breakdown → | 2018 | 404 |
| 13 | 2011 | 380 | |
| 14 | 1985 | 368 | |
| 15 | 1984 | 366 | |
| 16 | 2014 | 325 | |
| 17 | 2011 | 316 | |
| 18 | 2016 | 309 | |
| 19 | Cancer of the ovary, fallopian tube, and peritoneum: 2021 update Hit paper breakdown → | 2021 | 276 |
| 20 | 2012 | 264 |
About Michael Friedländer
Michael Friedländer is a scholar working on Oncology, Reproductive Medicine, Genetics, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology, having authored 493 papers that have together received 27.8k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (159 papers), PARP inhibition in cancer therapy (105 papers), BRCA gene mutations in cancer (97 papers), Endometrial and Cervical Cancer Treatments (47 papers), Cancer Treatment and Pharmacology (44 papers), Cancer Genomics and Diagnostics (32 papers), Cancer survivorship and care (30 papers) and Cancer Immunotherapy and Biomarkers (15 papers). The work is most often cited by research in Reproductive Medicine (7.0k citations), Oncology (13.3k citations), Obstetrics and Gynecology (1.9k citations), Cancer Research (3.6k citations) and Genetics (4.1k citations). Michael Friedländer has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include David W. Hedley, Ian W. Taylor, Elizabeth A. Musgrove, Catherine A. Rugg, M. William Audeh, Ursula A. Matulonis, James Carmichael, Clare L. Scott, David Goldstein and Matthew C. Kiernan. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, International Journal of Gynecological Cancer, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.